Weight loss was associated with improvements in: Blood pressure Lipid profiles Sleep apnoea Joint pain Quality of life These findings led regulatory bodies to approve semaglutide (Wegovy) and tirzepatide (Zepbound) for obesity treatment, even in the absence of diabetes signalling a paradigm shift in how weight and metabolic risk are medically managed
This effect was observed in human umbilical vein endothelial cells treated with exendin-4 [67]
These include mild soreness, redness, or a warm sensation at the injection site, brief lightheadedness or flushing shortly after administration, and occasional mild nausea in the first few sessions as the body adjusts to the lipotropic compounds
Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)
However, when you are breastfeeding, every supplement you consider comes with a vital question: Is it safe for the baby, and does it actually provide a benefit